Message from the President
What is the OECI
Cancer Economics and Benchmarking
Biobanks and Molecular Pathobiology
Collaboration for Good Practices with Patients
Cancer Outcomes Research
Accreditation and Designation
Supportive and Palliative Care
Dissemination and Communication
The Joint Action on Rare Cancers is a multi-stakeholder collaboration coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan, involving 18 Member States and the European Commission. There are 35 partners participating to JARC, including 8 Ministries of Health/Cancer Control Programme representatives (Cyprus, Czech Republic, France, Ireland, Italy, Malta, Poland, and Spain), 27 universities, public health institutions, cancer registries, cancer institutes, patients’ associations and other cancer societies/organisations such as Organisation of European Cancer Institutes, the European Society for Paediatric Oncology - SIOPE).
The Joint Action on Rare Cancers aims to:
prioritise all rare cancers in the agenda of the EU and the Member States with regards to national cancer plans, harmonisation of practices and funding of research;
develop innovative and shared solutions so that European Reference Networks on Rare Cancers can improve the quality of care, the clinical practice guidelines and research, the medical & patient education and the epidemiological surveillance.
The OECI is an Associate partner to JARC coordinating the Work-Package 5 “Assuring Quality of Care” with the objectives to:
map the existing networks of care for all 11 families of adult rare cancers across all Member States and identify gaps in current scenario and inequalities of patient access to resources;
propose consistent and Europe-wide systems-based standards for all families of rare cancers and the networks serving them.
design Quality Assurance systems or processes specific to rare cancers supplemental to the ERN requirements (which would, in time, enable networks to become ERNs). The aim would be to promote and assure the standards and criteria in Objective 2 above will be maintained, a system of continuous quality improvement be established, best practice shared, and equality of care met for rare cancers across Europe.
The general objective of BenchCan was to benchmark comprehensive cancer care & yield best practice examples in a way that contributes to improving the quality of interdisciplinary patient treatment. To achieve this, the BenchCan project, ended on June 2016, addressed 6 specific objectives:
to collect, compare and align by consensus formation the standards, recommendations and accreditation criteria of comprehensive cancer care in selected European countries.
to review and refine a benchmarking tool that can be applied to comprehensive cancer care through interdisciplinary patient treatment.
to pilot the benchmark tool with particular attention to operations management and best clinical practice.
to maximise knowledge exchange and sharing of best practice between providers of comprehensive cancer care in member states and regions.
to ensure compatibility of the benchmarking tools with existing cancer care resources and services.
to ensure the sustainability and longer-term benefits of the project.
This project was developed using the best available evidence and the involvement of various stakeholders, such as cancer institutes, cancer patients' umbrella organisations, like the European Cancer Patient Coalition, and other relevant European agencies. As a result of the project, comprehensive benchmarking tools have been developed, as well as good practice examples of clinical practice (including patient experience) and operations management processes have been identified, collected, and presented in a database.
As part of the BenchCan project a
has been elaborated and may be downloaded at:
It incorporates the developed benchmarking tools for cancer centres and cancer pathways and presents the necessary processes for carrying out an own benchmarking project by going through all the necessary detailed steps.